These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 25969894)

  • 21. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
    Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
    Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: results of an open label study.
    Huang LM; Chiu NC; Yeh SJ; Bhusal C; Arora AK
    Vaccine; 2014 Sep; 32(40):5177-84. PubMed ID: 25075804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
    Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
    Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
    Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM
    Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.
    Jackson LA; Jacobson RM; Reisinger KS; Anemona A; Danzig LE; Dull PM
    Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
    Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
    Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
    Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
    Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
    Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
    Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans.
    Toneatto D; Ismaili S; Ypma E; Vienken K; Oster P; Dull P
    Hum Vaccin; 2011 Jun; 7(6):646-53. PubMed ID: 21904120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.
    Lupisan S; Limkittikul K; Sosa N; Chanthavanich P; Bianco V; Baine Y; Van der Wielen M; Miller JM
    Clin Vaccine Immunol; 2013 Oct; 20(10):1499-507. PubMed ID: 23885033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.